CL2015003641A1 - Un método y aparato. para proporcionar un régimen de dosificación de proteína plasmática terapéutica. - Google Patents
Un método y aparato. para proporcionar un régimen de dosificación de proteína plasmática terapéutica.Info
- Publication number
- CL2015003641A1 CL2015003641A1 CL2015003641A CL2015003641A CL2015003641A1 CL 2015003641 A1 CL2015003641 A1 CL 2015003641A1 CL 2015003641 A CL2015003641 A CL 2015003641A CL 2015003641 A CL2015003641 A CL 2015003641A CL 2015003641 A1 CL2015003641 A1 CL 2015003641A1
- Authority
- CL
- Chile
- Prior art keywords
- dosage
- pharmacocinetic
- dosage regimen
- plasma protein
- patient
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 4
- 102000004506 Blood Proteins Human genes 0.000 title 1
- 108010017384 Blood Proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C99/00—Subject matter not provided for in other groups of this subclass
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Primary Health Care (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Databases & Information Systems (AREA)
- Computing Systems (AREA)
- Physiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Bioethics (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837421P | 2013-06-20 | 2013-06-20 | |
| US201361840969P | 2013-06-28 | 2013-06-28 | |
| US201361881214P | 2013-09-23 | 2013-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015003641A1 true CL2015003641A1 (es) | 2016-10-28 |
Family
ID=52111779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015003641A CL2015003641A1 (es) | 2013-06-20 | 2015-12-16 | Un método y aparato. para proporcionar un régimen de dosificación de proteína plasmática terapéutica. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140379629A1 (https=) |
| EP (3) | EP3879534A1 (https=) |
| JP (4) | JP2016526542A (https=) |
| KR (4) | KR102296042B1 (https=) |
| CN (2) | CN105592973B (https=) |
| AU (3) | AU2014287706B2 (https=) |
| BR (3) | BR122022000127A8 (https=) |
| CA (1) | CA2915472C (https=) |
| CL (1) | CL2015003641A1 (https=) |
| EA (1) | EA037962B1 (https=) |
| ES (1) | ES2882832T3 (https=) |
| GE (4) | GEAP201814039A (https=) |
| IL (3) | IL279313B (https=) |
| MX (3) | MX373454B (https=) |
| MY (2) | MY176173A (https=) |
| NZ (1) | NZ715216A (https=) |
| PH (1) | PH12015502800B1 (https=) |
| PL (1) | PL3010681T3 (https=) |
| SA (2) | SA515370289B1 (https=) |
| SG (1) | SG11201510515YA (https=) |
| UA (1) | UA118109C2 (https=) |
| WO (1) | WO2015006033A1 (https=) |
| ZA (1) | ZA201600100B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013088318A1 (en) * | 2011-12-13 | 2013-06-20 | Koninklijke Philips Electronics N.V. | Dose optimization based on outcome quality |
| US10083400B2 (en) | 2012-10-05 | 2018-09-25 | Diane R. MOULD | System and method for providing patient-specific dosing as a function of mathematical models updated to account for an observed patient response |
| US10325687B2 (en) * | 2013-12-06 | 2019-06-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| CA2944909A1 (en) | 2014-04-04 | 2015-10-08 | Bloodworks | Routine laboratory and point-of-care (poc) testing for hemostasis |
| US11062797B2 (en) * | 2014-10-10 | 2021-07-13 | Continuous Precision Medicine | Method and system for obtaining and using pharmacokinetic data in drug administration |
| AU2016245862A1 (en) | 2015-04-09 | 2018-02-22 | Diane R. Mould | Systems and methods for patient-specific dosing |
| WO2017136583A1 (en) * | 2016-02-02 | 2017-08-10 | Versartis, Inc. | Growth hormone treatment adherence system |
| KR102415992B1 (ko) | 2016-04-15 | 2022-07-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 약물동역학 약물 투약 요법을 제공하는 방법 및 장치 |
| JP6807015B2 (ja) * | 2016-06-13 | 2021-01-06 | ソニー株式会社 | 情報処理装置、情報処理方法、およびプログラム |
| US10896749B2 (en) * | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| US20190365317A1 (en) * | 2017-02-01 | 2019-12-05 | Shire Human Genetic Therapies, Inc. | Physiological sensing and therapeutic administration system and method |
| WO2020163441A1 (en) * | 2019-02-06 | 2020-08-13 | Optimdosing Llc | Smart multidosing |
| BE1027052A1 (fr) | 2019-02-14 | 2020-09-07 | Aardex Group | Procede d'assistance a la prise ou a l'acte d'un traitement therapeutique |
| US10970651B1 (en) * | 2019-12-02 | 2021-04-06 | Sas Institute Inc. | Analytic system for two-stage interactive graphical model selection |
| KR102420872B1 (ko) * | 2020-12-18 | 2022-07-14 | 포항공과대학교 산학협력단 | 강화학습과 약동-약력학 모델을 이용한 연속 약물 투여량 결정 방법 |
| CN113053508B (zh) * | 2021-03-29 | 2024-07-26 | 深圳市科曼医疗设备有限公司 | 基于触控屏的交互控制方法及装置 |
| US12444172B2 (en) * | 2022-11-28 | 2025-10-14 | GE Precision Healthcare LLC | Variable confidence machine learning |
| CN116844662B (zh) * | 2023-06-29 | 2026-03-27 | 中国科学技术大学 | 一种药剂投加方案的选取方法、装置和计算机可读介质 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07124125A (ja) * | 1993-11-04 | 1995-05-16 | S R L:Kk | 薬物投与解析システム |
| SI0796623T1 (en) * | 1996-03-20 | 2005-10-31 | Baxter Aktiengesellschaft | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| CA2218200A1 (en) * | 1996-12-09 | 1998-06-09 | Samuel David | Gpi-ceruloplasmin, analogs thereof, and methods of use |
| US6747002B2 (en) * | 1999-05-11 | 2004-06-08 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| US7860583B2 (en) | 2004-08-25 | 2010-12-28 | Carefusion 303, Inc. | System and method for dynamically adjusting patient therapy |
| AU2002212273B2 (en) * | 2000-09-15 | 2007-06-14 | Aaron Diamond Aids Research Centre | System and method for optimizing drug therapy for the treatment of diseases |
| TW200422917A (en) * | 2003-02-01 | 2004-11-01 | Baxter Int | Wireless medical data communication system and method |
| EP1642607A1 (en) * | 2004-10-04 | 2006-04-05 | Sanofi-Aventis Deutschland GmbH | Dose display mechanism for a drug delivery device |
| JP2006155071A (ja) * | 2004-11-26 | 2006-06-15 | Toshiba Sumiden Medical Information Systems Corp | 電子カルテ薬物療法指示実施システム |
| US20060183786A1 (en) * | 2005-02-16 | 2006-08-17 | Chi Mei Foundation Hospital | Injectable long-acting analgesic composition comprising an ester derivative of ketorolac |
| EP3703058A1 (en) * | 2005-11-29 | 2020-09-02 | Children's Hospital Medical Center | A method of selecting a medication for a patient |
| EP2286359A2 (en) * | 2008-03-27 | 2011-02-23 | Medtronic, Inc. | Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools |
| US8591454B2 (en) * | 2008-11-10 | 2013-11-26 | The Invention Science Fund I, Llc | Administering a therapeutic agent with more than one taggant |
| PL3326643T3 (pl) | 2009-12-06 | 2021-10-25 | Bioverativ Therapeutics Inc. | Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania |
-
2014
- 2014-06-20 WO PCT/US2014/043517 patent/WO2015006033A1/en not_active Ceased
- 2014-06-20 KR KR1020167001142A patent/KR102296042B1/ko active Active
- 2014-06-20 KR KR1020227015723A patent/KR20220065097A/ko not_active Ceased
- 2014-06-20 BR BR122022000127A patent/BR122022000127A8/pt not_active Application Discontinuation
- 2014-06-20 AU AU2014287706A patent/AU2014287706B2/en active Active
- 2014-06-20 GE GEAP201814039A patent/GEAP201814039A/en unknown
- 2014-06-20 GE GEAP201914559A patent/GEAP201914559A/en unknown
- 2014-06-20 BR BR112015031856A patent/BR112015031856A8/pt not_active Application Discontinuation
- 2014-06-20 EP EP21170633.8A patent/EP3879534A1/en active Pending
- 2014-06-20 JP JP2016521871A patent/JP2016526542A/ja active Pending
- 2014-06-20 CN CN201480046279.5A patent/CN105592973B/zh active Active
- 2014-06-20 SG SG11201510515YA patent/SG11201510515YA/en unknown
- 2014-06-20 EP EP14823224.2A patent/EP3010681B1/en active Active
- 2014-06-20 CN CN202010499366.3A patent/CN111508557B/zh active Active
- 2014-06-20 UA UAA201600443A patent/UA118109C2/uk unknown
- 2014-06-20 KR KR1020217026984A patent/KR102352133B1/ko active Active
- 2014-06-20 EP EP17197995.8A patent/EP3309696A1/en not_active Withdrawn
- 2014-06-20 GE GEAP201414039A patent/GEP20186882B/en unknown
- 2014-06-20 EA EA201690048A patent/EA037962B1/ru unknown
- 2014-06-20 MY MYPI2015704622A patent/MY176173A/en unknown
- 2014-06-20 MX MX2015017878A patent/MX373454B/es active IP Right Grant
- 2014-06-20 KR KR1020227001162A patent/KR102397974B1/ko active Active
- 2014-06-20 IL IL279313A patent/IL279313B/en unknown
- 2014-06-20 ES ES14823224T patent/ES2882832T3/es active Active
- 2014-06-20 PL PL14823224T patent/PL3010681T3/pl unknown
- 2014-06-20 NZ NZ715216A patent/NZ715216A/en unknown
- 2014-06-20 CA CA2915472A patent/CA2915472C/en active Active
- 2014-06-20 BR BR122020013811A patent/BR122020013811A8/pt not_active Application Discontinuation
- 2014-06-20 MY MYPI2020003916A patent/MY195911A/en unknown
- 2014-06-20 US US14/311,113 patent/US20140379629A1/en not_active Abandoned
- 2014-06-20 GE GEAP201414559A patent/GEP20196990B/en unknown
-
2015
- 2015-12-16 PH PH12015502800A patent/PH12015502800B1/en unknown
- 2015-12-16 CL CL2015003641A patent/CL2015003641A1/es unknown
- 2015-12-17 SA SA515370289A patent/SA515370289B1/ar unknown
- 2015-12-17 IL IL243208A patent/IL243208B/en active IP Right Grant
- 2015-12-17 SA SA521430246A patent/SA521430246B1/ar unknown
- 2015-12-18 MX MX2023000359A patent/MX2023000359A/es unknown
- 2015-12-18 MX MX2020004112A patent/MX2020004112A/es unknown
-
2016
- 2016-01-06 ZA ZA2016/00100A patent/ZA201600100B/en unknown
-
2017
- 2017-12-07 AU AU2017272293A patent/AU2017272293B2/en active Active
-
2019
- 2019-05-22 JP JP2019095949A patent/JP6813237B2/ja active Active
-
2020
- 2020-04-21 AU AU2020202664A patent/AU2020202664B2/en active Active
- 2020-05-21 IL IL274848A patent/IL274848A/en active IP Right Grant
- 2020-12-11 JP JP2020205945A patent/JP7060291B2/ja active Active
-
2022
- 2022-04-11 JP JP2022065039A patent/JP7398031B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015003641A1 (es) | Un método y aparato. para proporcionar un régimen de dosificación de proteína plasmática terapéutica. | |
| IL260852B (en) | Methods, devices and systems for pulmonary delivery of active agents | |
| CL2017003033A1 (es) | Dispositivo de monitorización para la aplicación de un fármaco con una pluma de fármaco, con registro, comunicación y alarmas. | |
| CL2017003005A1 (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
| CL2016000354A1 (es) | Modulación de la inmunidad tumoral | |
| CL2016000055A1 (es) | Métodos para tratar o prevenir afecciones oftalmológicas | |
| CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
| MX2017015186A (es) | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| BR112016028643A2 (pt) | ?dispositivo de vedação e sistema de entrega? | |
| EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
| TWD190432S (zh) | 鼻管 | |
| MX2015008685A (es) | Tratamiento de artritis psoriasica usando apremilast. | |
| MX388858B (es) | Reducción de la viscosidad de formulaciones farmacéuticas | |
| MX2017016657A (es) | Dispositivos y metodos para administracion y mezcla de farmaco, y entrenamiento de tecnicas apropiadas para ello. | |
| BR112015027477A8 (pt) | bolus, seus usos, e kit | |
| MX2017003513A (es) | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia. | |
| CL2015002592A1 (es) | Método y sistema para grabar contenidos recomendados por medio del uso de agrupadores de contenidos | |
| CL2016000641A1 (es) | Un controlador para un dispositivo para administrar un medio de contraste que comprende un agente de contraste radiológico en un paciente usando un inyector, y método para determinar el volumen óptimo de un medio de contraste que comprende un agente de contraste radiológico que ha de administrarse en un paciente, antes de la administración. | |
| CO7461127A2 (es) | Código para la configuración de un dispositivo de atención al paciente | |
| EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
| EA201692432A1 (ru) | Способ и устройство для определения времени распадаемости пленочной лекарственной формы | |
| CL2016000944A1 (es) | Nueva formulación de ganadotropinas | |
| AR103188A1 (es) | Formulaciones de paracetamol inyectables | |
| CL2016000414A1 (es) | Un método para un sistema de procesamiento de líquidos que comprende las etapas de proporcionar un primer flujo de líquido a través de una geometría predeterminada, determinar la velocidad del flujo y la caída de presión a través de dicha geometría, proporcionar un segundo flujo de líquido a través de una geometría predeterminada, determinar la velocidad u caída de presión de dicha segunda geometría y calcular la consistencia y el índice de comportamiento de flujo; y dispositivo asociado. |